Interaction between Fluconazole and Amphotericin B in Mice with Systemic Infection Due to Fluconazole-Susceptible or -Resistant Strains of Candida albicans-Reference-Cited by-同舟云学术

Interaction between Fluconazole and Amphotericin B in Mice with Systemic Infection Due to Fluconazole-Susceptible or -Resistant Strains of Candida albicans

Published:1999-12 Issue:12 Volume:43 Page:2841-2847
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Louie Arnold¹²,Banerjee Partha¹²,Drusano George L.¹³,Shayegani Mehdi²,Miller Michael H.¹³

Affiliation:

1. Division of Infectious Diseases1 and

2. Wadsworth Center, New York State Department of Health, Albany, New York 122012

3. Clinical Pharmacology,3 Department of Medicine, Albany Medical College, Albany, New York 12208, and

Abstract

ABSTRACT The interaction between fluconazole (Flu) and amphotericin B (AmB) was evaluated in a murine model of systemic candidiasis for one Flu-susceptible strain (MIC, 0.5 μg/ml), two strains with intermediate Flu resistance (Flu mid-resistant strains) (MIC, 64 and 128 μg/ml), and one highly Flu-resistant strain (MIC, 512 μg/ml) of Candida albicans . Differences in fungal densities in kidneys of infected mice after 24 h of therapy and in survival rates at 62 days of mice treated with an antifungal drug or a combination of antifungal drugs for 4 days were compared. For the Flu-susceptible and Flu mid-resistant strains, the combination of Flu and AmB was antagonistic, as shown by both quantitative culture results and survival. The interaction was additive for the highly Flu-resistant strain. These results suggest that the combination of Flu and AmB should be used with caution in infections due to fungi that are usually susceptible to both antifungal agents and as empirical antifungal drug therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.43.12.2841

Reference24 articles.

1. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies

2. A new look at the statistical model identification.;Akaike H.;IEEE Trans. Automated Control,1974

3. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.;Anaissie E. J.;Clin. Infect. Dis.,1996

4. Banerjee P. Liu Q.-F. Louie A. Shayegani M. Taber H. Drusano G. Miller M. Comparison of checkerboard isobolograms and computer generated 3D-plots for evaluation of the in-vitro interactions between antifungal drugs abstr. C-252a Abstracts of the 97th General Meeting of the American Society for Microbiology. 1997 164 American Society for Microbiology Washington D.C.

5. Discrepant Results of Amphotericin B Assays on Fresh Versus Frozen Serum Samples

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro–In Vivo Correlation of Posaconazole–Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels;Journal of Fungi;2023-04-01

2. Sustained Release of Antifungal and Antibacterial Agents from Novel Hybrid Degradable Nanofibers for the Treatment of Polymicrobial Osteomyelitis;International Journal of Molecular Sciences;2023-02-07

3. In Vivo Efficacy of Amphotericin B against Four Candida auris Clades;Journal of Fungi;2022-05-11

4. In vivo antifungal activities of farnesol combined with antifungal drugs against murine oral mucosal candidiasis;Biofouling;2021-09-14

5. Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations;Journal of Fungi;2021-02-04